Cantor Fitzgerald Weighs in on MRK FY2025 Earnings
Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Merck & Co., Inc. in a note issued to ...
Arcutis Biotherapeutics: After Outstanding 2024, Shares May Face Cooling Off Period
Financial writer analysis of Arcutis Biotherapeutics, Inc. stock surge and potential growth, FDA approvals, and partnerships ...
AstraZeneca's Growth Potential: 6 Reasons For A Buy Rating
AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.
RJK Jr.'s Involvement In Merck Lawsuit Faces Scrutiny Ahead Of Senate Hearing
Robert F. Kennedy Jr., President Donald Trump‘s nominee for Health and Human Services Secretary, is facing scrutiny over his decision to retain financial interests in ongoing litigation against Merck ...
Jefferies Reaffirms Their Buy Rating on Merck & Company (MRK)
In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Merck & Company (MRK – Research Report). The ...
Kennedy Jr. to keep vaccine suit stake if confirmed as health chief, FT says
Robert Kennedy Jr. will keep his share of any windfall from litigation against Merck (MRK) even if he becomes Donald Trump’s top U.S. health ...